Printer Friendly

Amphora to Present Posters on Promising Results From AKT and Target Tyrosine Kinase (TTK) Programs at AACR-NCI-EORTC International Conference.

RESEARCH TRIANGLE PARK, N.C., Nov. 8 /PRNewswire/ -- Amphora Discovery Corporation today announced that abstracts containing promising data from Amphora's preclinical AKT and Targeted Tyrosine Kinase (TTK) programs have been accepted for poster presentation at the AACR-NCI-EORTC International Conference in Philadelphia, Pennsylvania November 14 -18, 2005.
 Details are as follows:

 - Presentation Time: November 15th 12.30 - 2.30 pm.; 5.30 - 7.30 pm
 Poster Session A
 Title: Multi-Targeted Tyrosine Kinase Inhibitors of FLT3 + cKIT + PDGFR
 for the Treatment of Hematological Malignancies and Solid Tumors.
 Poster A264
 - Amphora will present data on several proprietary series of inhibitors
 that are highly selective for the combination of FLT3 + cKIT + PDGFR
 over a broad panel of 96 enzymes. These inhibitors have been rapidly
 optimized and demonstrate low nanomolar potency in blocking
 proliferation in a leukemia cell line.

 - Presentation Time: November 17th 12.30 - 2.30 pm.; 5.30 - 7.30 pm
 Session C
 Title: Is One Enough? - Development of Highly Selective AKT1 Inhibitors
 as a Targeted Therapy for Cancer. Poster C147
 - Amphora will present the latest data on potent compounds that are
 highly selective for the AKT1 isoform. These compounds display
 nanomolar inhibitory activity and are >100-fold selective over AKT2,
 AKT3, and 96 other enzyme targets. Cellular assays addressing
 apoptosis, proliferation, and phosphorylation of downstream substrates
 with the AKT1 selective inhibitors will be shown.

 About Amphora

Amphora is a biopharmaceutical company with a pipeline of internally discovered product candidates that address oncology and inflammation indications. The company is engaged in the discovery and development of superior, highly-selective, small molecule medicines for both large and small markets. By leveraging its robust and proprietary chemical-biological database, Amphora is pursuing a next generation drug discovery strategy. Amphora's preclinical programs include AKT1, p38, and TRPV1 as well as partnered programs. For more information, please visit the company's web site at

CONTACT: Tracy Thompson, Corporate Communications of Amphora, +1-919-287-6177, or

Web site:
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Nov 8, 2005
Previous Article:Oh, Christmas Tree: Pining for Perfection.
Next Article:Aleris Announces Significantly Improved Third Quarter 2005 Net Income of $31.5 Million.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters